Literature DB >> 10780203

[Frequency and costs of hospital stays for hypoglycemia in France in 1995].

M P Allicar1, F Mégas, S Houzard, A Baroux, F Le Thai, B Augendre-Ferrante.   

Abstract

OBJECTIVES: Diabetes is a highly prevalent chronic disease causing serious complications. Hypoglycemia is the most frequent, the most serious, and the most feared by patients and families. Hospitalization may be necessary and can be costly. The main objective of this study was to determine the number of cases of hypoglycemia cared for annually in France in an inpatient setting and to estimate the annual financial impact of hospitalizations. PATIENTS AND METHODS: The number of hypoglycemias seen annually by physician s in France and the frequencies of hospitalizations for hypoglycemia were determined from a literature search. Complementary data on costs were obtained from the national PMSI mission. Our sample included 817 hospital stays between 1994 and 1995.
RESULTS: In 1992, physicians in France cared for 40,000 episodes of hypoglycemia. There were 10,800 hospitalizations. In 9 out of 10 cases, the hospital stay lasted several days and, despite hospitalization, 1.9% of the patients died. Mean total medical cost of a hospital stay for hypoglycemia was 14,000 FF ($2,100) (median 10,000 FF, range 1,200-120,000 FF). Mean length of stay was 6.6 days. DISCUSSION: Mean unit cost for hospital stays for hypoglycemia is high. Based on the 1993 SESI survey, the probable annual cost for the society for hospital care of patients with hypoglycemia was an estimated 108 to 151 million FF ($16-22 million) in 1995. This figure only takes into account the visible cost of caring for hypoglycemia patients. Ambulatory care was not taken into consideration. Education, for the patient and family, is fundamental for the prevention and treatment of hypoglycemia.
CONCLUSION: It is important to have this estimation due to the absence of a medicoeconomic study on ambulatory and hospital care for hypoglycemia. Complementary studies should be conducted to estimate the total annual cost of hypoglycemia in France.

Entities:  

Mesh:

Year:  2000        PMID: 10780203

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  6 in total

1.  Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management.

Authors:  Sylvie Dejager; Anja Schweizer
Journal:  Diabetes Ther       Date:  2011-02-08       Impact factor: 2.945

Review 2.  Hypoglycaemia in Type 2 diabetes.

Authors:  S A Amiel; T Dixon; R Mann; K Jameson
Journal:  Diabet Med       Date:  2008-01-21       Impact factor: 4.359

3.  Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.

Authors:  Julio Rosenstock; Vivian Fonseca; Stefan Schinzel; Marie-Paule Dain; Peter Mullins; Matthew Riddle
Journal:  J Diabetes Complications       Date:  2014-04-16       Impact factor: 2.852

4.  Retrospective analysis of medical costs and resource utilization for severe hypoglycemic events in patients with type 2 diabetes in Japan.

Authors:  Yuika Ikeda; Takekazu Kubo; Eisei Oda; Machiko Abe; Shigeru Tokita
Journal:  J Diabetes Investig       Date:  2018-11-17       Impact factor: 4.232

5.  Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia.

Authors:  J Reviriego; R Gomis; J P Marañés; W Ricart; P Hudson; J A Sacristán
Journal:  Int J Clin Pract       Date:  2008-05-16       Impact factor: 2.503

Review 6.  Hypoglycemia: The neglected complication.

Authors:  Sanjay Kalra; Jagat Jyoti Mukherjee; Subramanium Venkataraman; Ganapathi Bantwal; Shehla Shaikh; Banshi Saboo; Ashok Kumar Das; Ambady Ramachandran
Journal:  Indian J Endocrinol Metab       Date:  2013-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.